CardioComm Solutions Issue Stock Options
CardioComm Solutions Issue Stock Options
Toronto, Ontario--(Newsfile Corp. - July 28, 2022) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has issued 125,000 stock options to Etienne Grima, the Company's CEO, in accordance with his employment agreement. The options are exercisable at $0.05 per Share for five years from the date of grant and vest immediately. The grant is subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.
安大略省多伦多-(Newsfile Corp.-2022年7月28日)-美国心脏通讯解决方案公司(TSXV：EKG)(“心电联动“或”公司)，一家全球消费者心脏监测和医疗心电图仪的医疗供应商(心电信号“)软件解决方案公司宣布，它已根据公司首席执行官Etienne Grima的雇佣协议向他发行了125,000份股票期权。这些期权可在授予和立即授予之日起五年内以每股0.05美元的价格行使。授予受制于公司股票期权计划、多伦多证券交易所创业板政策和适用的证券法的规定。
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at and .
欲了解更多有关HearoComm公司产品的信息，以及有关HeartCheck™心电设备集成的进一步更新，请访问该公司的网站和。
About CardioComm Solutions
关于心通解决方案
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
心脏通讯解决方案公司的专利和专有技术用于记录、观看、分析和存储心电，用于心脏病患者的诊断和管理。产品通过外部分销网络和北美销售团队销往世界各地。心脏通信解决方案公司已获得国际标准化组织13485认证，符合美国食品和药物管理局的要求，并获得欧盟(CE标志)、美国食品和药物管理局(FDA)和加拿大卫生部(Health Canada)的许可。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
欲了解更多信息，请联系：
首席执行官艾蒂安·格里马
1-877-977-9425 x227
邮箱：egrima@core ocomsoltions.com
邮箱：Investor.Relationship@Hearocomsoltions.com
Forward-looking statements
前瞻性陈述
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
本新闻稿可能包含有关心脏通信解决方案公司的财务状况、经营和业务结果以及心脏通信解决方案公司与这些项目有关的某些计划和目标的前瞻性陈述和前瞻性信息。这些陈述和信息反映了管理层目前的信念，并以管理层目前掌握的信息为基础。就其性质而言，前瞻性陈述和前瞻性信息涉及风险和不确定性，因为它们与事件有关，并取决于未来发生的情况，而且有许多因素可能导致实际结果和事态发展与这些前瞻性陈述和前瞻性信息明示或暗示的情况大不相同。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在评估这些陈述时，读者不应过分依赖前瞻性陈述和前瞻性信息。除适用法律要求外，公司不承担更新本新闻稿中包含的前瞻性陈述和前瞻性信息的任何义务，包括但不限于国家文书51-102(持续披露义务).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所风险交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问